Emmaus Life Sciences, Inc. (EMMA)
OQB · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Emmaus Life Sciences, Inc.
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. It has a license agreement with Kainos Medicine, Inc., which includes the patent rights of IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, such as leukemia, lymphoma, and solid tumor cancers. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 2.8M | 3.4M | 3.9M | 2.0M |
| Gross Profit | 2.7M | 3.1M | 3.6M | 1.8M |
| Operating Income | -370K | 695K | 886K | -823K |
| Net Income | -1.1M | -2.1M | -2.0M | -3.3M |
| Diluted EPS | $-0.02 | $-0.03 | $nan | $-0.05 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 18.4M | 29.6M | 16.7M | 12.5M |
| Gross Profit | 15.8M | 28.3M | 15.5M | 11.6M |
| Operating Income | -6.6M | 3.5M | -1.9M | 231K |
| Net Income | -10.6M | -3.7M | -6.5M | -7.5M |
| Diluted EPS | $-0.21 | $-0.07 | $-0.10 | $-0.12 |